Tango Therapeutics (TNGX) Accumulated Expenses (2020 - 2026)

Tango Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $9.1 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 12.59% year-over-year to $9.1 million in Q1 2026; TTM through Mar 2026 was $9.1 million, a 12.59% decrease from a year earlier, with the FY2025 full-year figure at $17.8 million, up 7.65% from the prior year.
• Accumulated Expenses declined to $9.1 million in Q1 2026 per TNGX's latest filing, from $17.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $17.8 million in Q4 2025 and bottomed at $5.6 million in Q2 2025.
• The 5-year median for Accumulated Expenses is $13.2 million (2023), against an average of $12.5 million.
• Across the five-year window, Accumulated Expenses soared 4736.23% in 2022 and plunged 66.64% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $17.5 million in 2022, then plunged by 54.79% to $7.9 million in 2023, then surged by 108.56% to $16.5 million in 2024, then climbed by 7.65% to $17.8 million in 2025, then sank by 48.94% to $9.1 million in 2026.
• Per Business Quant, the three latest TNGX Accumulated Expenses figures stand at $9.1 million (Q1 2026), $17.8 million (Q4 2025), and $6.5 million (Q3 2025).